Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up

Jingwen Niu; Yuhang Li; Xu Chen; Hongxia Sheng; Chong Tian; Hongmei Ning; Jiangwei Hu; Jianlin Chen; Botao Li; Jun Wang; Xiao Lou; Na Liu; Yong-Feng Su; Yao Sun; Zhuoqing Qiao; Lei Wang; Yu Zhang; Sanchun Lan; Jing Xie; Jing Ren; Bo Peng; Shenyu Wang; Yanping Shi; Long Zhao; Yijian Zhang; Hu Chen; Bin Zhang; Liangding Hu

doi:10.3389/fimmu.2024.1436653

Abstract

Mesenchymal stromal cells (MSCs) have been extensively studied as a potential treatment for steroid refractory acute graft-versus-host disease (aGVHD). However, the majority of clinical trials have focused on bone marrow-derived MSCs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Niu et al. (2024) studied this question.

synapsesocial.com/papers/68e5c1e1b6db6435875592ef https://doi.org/10.3389/fimmu.2024.1436653

View Full Paper

Ask AI

Bookmark

Share

Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up

Abstract

Discussion

Cite This Study

Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up

Abstract

Discussion

Cite This Study

Keep reading

Keep reading